|Videos|July 18, 2014
Future Immunotherapy Strategies in Cancer
Advertisement
Episodes in this series
For High-Definition, Click
The success of immunotherapies will change the way clinical trials are conducted and reported, suggests Louis M. Weiner, MD. Additionally, the success of these agents will set the bar higher for future therapies.
In this segment, panelists discuss their thoughts on future immunotherapy strategies, including treatment strategies that incorporate chimeric antigen receptor therapies, tumor infiltrating lymphocytes, and vaccines.
View the video, to hear the discussion.
Advertisement
Related to this article
The combination nearly doubled the confirmed response rate in the randomized phase 2 portion of HexAgon-HN, with the greatest benefit in HPV-positive disease.
TRE-515 earned fast track status in combination with KRAS inhibitors for G12C-mutated NSCLC after anti–PD-(L)1 therapy and platinum-based chemotherapy.
An NDA for zipalertinib in EGFR exon 20 insertion–positive NSCLC is being supported by phase 3 REZILIENT3 data.
The top 5 OncLive TV videos of the week cover insights in breast cancer, PV, myeloma, and CLL.
The FDA approved lirafugratinib in FGFR2+ cholangiocarcinoma and belzutifan plus lenvatinib in advanced ccRCC, and more.
FDA grants priority review to durvalumab plus enfortumab vedotin for cisplatin-ineligible MIBC based on positive phase 3 VOLGA data.
The addition of the β-catenin pathway inhibitor tegavivint to osimertinib produced deep responses in a phase 1b study in first-line EGFR-mutated NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
Epcoritamab Plus R-CHOP Meets PFS End Point in Newly Diagnosed DLBCL
2
Botensilimab Plus Balstilimab Yields Durable OS in Recurrent Ovarian Cancer
3
‘Our Impact Will Be Broad and Transformative’: Wells Messersmith, MD, Takes the Reins at CU Anschutz Cancer Center
4
FSHR-Directed CAR T-Cell Therapy Yields Instance of Stable Disease in Recurrent Ovarian Cancer
5